off label tirzepatide FDA approves Eli Lilly's diabetes drug Mounjaro for obesity under new name, Zepbound GLP-1 Informed Consent & Risk

The second reason is acid

Patients switching from brand-name to compounded semaglutide experience no lag in blood sugar control, and many report faster results because they're able to remain consistent with treatment without insurance delays or prior-authorization bottlenecks

The supporting laboratory papers, the ones with the synaptogenesis data, published across 2012 to 2014

While constipation is often most noticeable after starting Mounjaro or increasing the dose, symptoms usually improve as the body adjusts, although the duration varies between individuals

Strategies for Sustaining Weight Loss Without Ongoing GLP-1 Treatment Successful weight maintenance after stopping GLP-1 medication requires intentional planning rather than hoping previous habits stick

6 (Suppl 2): 51S209S